Quantinno Capital Management LP Boosts Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Quantinno Capital Management LP increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 245.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,061 shares of the biotechnology company’s stock after purchasing an additional 56,909 shares during the quarter. Quantinno Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $762,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $123,452,000. Deerfield Management Company L.P. grew its position in shares of BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after buying an additional 7,310,745 shares during the period. Perceptive Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $24,668,000. Finally, RFG Advisory LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $27,329,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.4%

BCRX opened at $9.70 on Wednesday. The stock has a fifty day simple moving average of $9.55 and a two-hundred day simple moving average of $8.88. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -6.47 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. During the same quarter in the previous year, the business posted $0.15 EPS. The company’s quarterly revenue was up 33.6% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada lowered their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.